Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI – Get Free Report)’s stock price traded up 1.3% during trading on Friday . The stock traded as high as $0.18 and last traded at $0.16. 1,103,124 shares traded hands during trading, an increase of 5% from the average session volume of 1,049,327 shares. The stock had previously closed at $0.16.
Analyst Ratings Changes
A number of brokerages have recently commented on CLDI. HC Wainwright lowered their price target on Calidi Biotherapeutics from $11.00 to $2.00 and set a “buy” rating for the company in a research note on Thursday, March 21st. Robert W. Baird lowered their target price on shares of Calidi Biotherapeutics from $9.00 to $4.50 and set an “outperform” rating for the company in a research note on Thursday, March 21st.
Get Our Latest Stock Analysis on CLDI
Calidi Biotherapeutics Stock Up 1.3 %
Calidi Biotherapeutics Company Profile
Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors.
Recommended Stories
- Five stocks we like better than Calidi Biotherapeutics
- Health Care Stocks Explained: Why You Might Want to Invest
- Comprehensive Analysis of PayPal Stock
- How to Evaluate a Stock Before Buying
- Intuitive Surgical Stock Can Trend Much Higher This Year
- How to Use Stock Screeners to Find Stocks
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Calidi Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calidi Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
